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Summary The chromatin-bound enzyme adenosine diphosphate ribosyl transferase is activated by DNA-
damaging agents. Substances that inhibit the enzyme, such as benzamide analogues, are known to increase the
cytotoxicity of ionising radiation and cytotoxic drugs. The purpose of the present study was to investigate
whether the anti-emetic drug metoclopramide, a benzamide derivative (4-amino-N-2-(diethylaminoethyl)-5-
chloro-2-methoxybenzamide; MCA), potentiates the, effect of cisplatin (cis-diammine-dichloroplatinum;
CDDP) on squamous cell carcinoma (SCC). For that purpose human SCC of the head and neck (i.e. tumour
line AB and EH) xenografted to nude mice were used. Two administration schedules were tested: (a) MCA
(2.Omgkg-1 i.p.) one hour before CDDP (7.5mgkg-' i.p.); and (b) MCA (3 x 2.Omgkg-1) given
concomitant to, 24 and 48 hours after CDDP (7.5mgkg-1) administration. Treatment efficacies were
compared using the area under the growth curves (AUC), tumour volumes and specific growth delay (SGD).
There was no mortality and no weight loss of significance in any treatment group. MCA alone did not induce
any significant reduction in AUC, tumour volume or SGD with either treatment schedule. CDDP alone gave
a significant reduction of tumour growth in tumour line AB but not in tumour line EH. In schedule (a) the
addition of MCA did not give any additive effect. However, in schedule (b), for both tumour lines, MCA
enhanced the effect of CDDP by significantly reducing the AUC (AB: P<0.0001; EH: P<0.001) and
increasing SGD (AB: P<0.012; EH: P<0.001) when compared to the tumours given CDDP alone. These
effects were observed at a MCA dose currently being administered to humans.
One important strategy in designing effective cancer chemo-
therapeutic drugs is defining the mechanism of cell death.
Activation of the chromatin-bound enzyme adenosine
diphosphate ribosyl transferase (ADPRP) and the subse-
quent depletion of energy metabolites, such as NAD and
ATP, are involved in the cellular response to induced DNA
damage that leads eventually to cell death (Berger, 1986).
lonising radiation and/or most cancer chemotherapeutic
drugs induce DNA damage, and as a consequence induce
ADPRT activity, thereby indicating a role in the mechanism
of DNA repair (Berger, 1986; Ward, 1986; Skidmore et al.,
1979).
Nicotinamide, benzamide, 3-aminobenzamide and purine
analogues, such as theophylline and other xanthines, have
been shown to be effective sensitisers of the cytotoxic action
induced by radiation and cancer chemotherapeutic drugs in
both cell culture and animal tumour model systems (Ben-
Hur, 1984; George et al., 1986; Thraves et al., 1985; Kjellen
et al., 1986; Horsman et al., 1986; Nduka et al., 1980;
Smulson et al., 1977). These sensitising properties have been
attributed to inhibition of ADPRT, with a concomitant
decrease in DNA repair ability.
The common structural feature that was shown to be of
importance to maintain a high degree of inhibition of
ADPRT was the presence of a ring-carboxamide group
(Sims et al., 1982). Metoclopramide, a poly-substituted-N-
tertiary amino alkyl benzamide (i.e. with a ring but substi-
tuted carboxamide group), is well established as a successful
antiemetic treatment for chemotherapy-induced nausea and
vomiting (see Gralla et al., 1981). However, whether N-
substituted benzamide analogues also possess properties that
modulate ADPRT is not known. Cisplatin (cis-diammine-di-
chloroplatinum; CDDP) is a heavy metal complex with
alkylating properties which allow bifunctional linking to
DNA and thus it has cytotoxic properties (Rosenberg et al.,
1969). Since CDDP chemotherapeutic regimens induce nau-
sea, metoclopramide (MCA) is often co-administered as an
anti-emetic drug. The purpose of the present study was to
investigate whether metoclopramide could sensitise the effect
of CDDP. For this we have used human squamous cell
carcinomas of the head and neck xenografted to nude mice.
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Materials and methods
Mice
Five- to eight-week old BALB/c male and female nude mice
were used. The colony was kept under sterile but not specific
pathogen-free conditions (Wennerberg, 1984).
Tumour lines
Two xenografted human squamous cell carcinoma (SCC)
lines were used for the study. Tumour line AB, originating
from a poorly differentiated SCC of the nasal cavity, was in
its 81st to 85th passage. Tumour line EH, originating from a
poorly differentiated SCC of the tonsil, was in its 62nd
passage. Histopathological examination of the xenografted
tumours revealed that they retained histology and immuno-
histochemical analysis of human P2-microglobulin and cellu-
lar retinol-binding protein, confirming that the tumour cells
were of human SCC origin. Tumour volume doubling time
(DT) and ploidy were checked regularly (i.e. once every three
months).
Tumour grafts were serially transferred by subcutaneous
inoculation of 2 x 2 x 2mm pieces into the dorsal side of
mice, one on each side. The double tumour inoculation site
method was used since growth pattern analyses have not
revealed any host-induced uniformity of growth, which is in
accordance with the findings of Warenius et al. (1980) and
Spang-Thomsen et al. (1980).
Tumour volume measurements
Two orthogonal diameters of the tumour were measured
with vernier calipers. The tumour volume was calculated
according to the formula:
length xwidth2 Volume= 2
Tumour volume calculated according to this formula corre-
lates well with measured tumour volume (Fodstad et al.,
1980; Osieka et al., 1977). The tumour volume and the
weight of the animals were recorded three days before start
of treatment and then two to three times weekly. Only
animals with growing tumours were included in the study.
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Endpoints
Two different endpoints were used.
1. The area under the growth curve (AUC). Relative
tumour size (RTS, i.e. tumour size at the time of measure-
ment in relation to tumour size at the time of the first drug
administration) was calculated from the actual volumes. To
obtain a normal distribution of RTS values, the log of RTS
was used. The AUC was calculated and used as the endpoint
from the growth curves of the log RTS-values vs. time. Such
a measure accounts for both degree and duration of inhibi-
tion, and the daily fluctuations will be smoothed out in the
process, leading to area calculation (Lesser et al., 1980).
2. Specific growth delay (SGD). SGD was calculated
-according to Berman & Steel (1984). From the growth curves
of the log RTS versus time the time taken for each treated
and control tumour to double in volume (DT) was obtained.
Tumour growth delay was calculated as the difference
between the DT of the individual tumour and the mean DT
for control tumours. When this was divided with the mean
DT for control tumours the SGD was obtained. SGD can be
regarded as the number of DT gained by the treatment. In
order to avoid potential pitfalls (Begg, 1980) we analysed
growth curves of individual tumours rather than mean of
groups.
Drugs
The dose of CDDP administered was given to correspond to
the maximum tolerated dose (MTD) for tumour-bearing
nude mice. At the MTD the mice should have weight loss of
10% in the week following the first injection. Death occur-
ring within two weeks after the last injection was considered
a toxic death, and the animal was excluded from evaluation.
CDDP and MCA were obtained as commercially available
preparations from Bristol Laboratories, Syracuse, NY, USA
(Platinol), and H. Lundbeck A/S, Copenhagen, Denmark
(Primperan), respectively. The drugs were diluted to proper
concentrations before administration intraperitoneally in
volumes of 0.01-0.02ml per g body weight.
The dose of CDDP applied in this study (7.5mgkg 1) was
based on results in previously reported dose-response studies
(Wennerberg et al., 1984, 1988). In CDDP-sensitive lines it
gives a significant inhibition of tumour growth with < 10%
mortality and < 10% weight loss. The MCA dose was
calculated from the dose currently being used in humans
(Gralla et al., 1981; Trope et al., 1985).
Two administration schedules were tested: (a) MCA
(2.Omgkg-' i.p.) one hour before CDDP (7.5mgkg-' i.p.);
and (b) MCA (3 x 2.0mgkg-1) given concomitantly, 24 and
48h after CDDP (7.5mgkg-1) administration. In both sche-
dules the combined treatment was compared with CDDP
alone, MCA alone and with NaCl-treated control tumours.
The first schedule was tested on tumour line AB and the
second on both.
Schedule (a) was first tried. Since MCA -given before
CDDP did not enhance the effect of CDDP (see Results),
schedule (b) was applied. The schedule (b) sequence was
chosen since it is known that both MCA and CDDP have
short half-lifes (T112 values of 157 and 15min, respectively:
Bateman et al., 1980; Vermorken et al., 1984). In addition,
although CDDP has a short T112 it also has profound effects
on DNA synthesis and cell cycle phase distribution for 48 h
after drug administration (Wennerberg et al., 1984).
Statistics
Data analysis was carried out using the RS/1 data analysis
system (Bolt, Beranek and Newman Research Systems, MA,
USA). Normality of distributions was tested with the Wilk-
Shapiro test. Differences within each experiment were tested
with one-way analysis of variance (ANOVA) and then
between different treatments with Student's t test (population
normal) or Mann-Whitney U test (population not normal).
Differences were tested at a significance level of P=0.05.
Results
There was no mortality in any treatment group in any
schedule. NaCl administration three times caused per se a
temporary retardation of weight gain, as did MCA alone.
CDDP-containing regimens induced up to 8% weight loss,
but weight gain was resumed as soon as drug administration
was ended (Figure 1).
Tumour growth was evaluated by one-way analysis of
variance (ANOVA) for all treatment groups before com-
parisons between experimental groups were carried out to
evaluate MCA enhancement of CDDP antitumour activity.
The P values are given in Tables I to III. In the two first
experiments (Tables I and II) the hypothesis that the samples
o 2 4 6 8 10 12 14 16 18 20 22
Days after start of treatment
Figure 1 Weight curves showing changes in median values
relation to starting weight for control and treated animals in
schedule (b) CDDP: cisplatin, MCA: metoclopramide, C +M:
CDDP+MCA. (Points are median of 8-10 animals.)
Table I Specific growth delay (SGD) and area under the growth
curve (AUC) for tumours of tumour line AB treated according to
schedule (a)
Treatment Mean SGD Mean AUC
group n +s.e.m. +s.e.m.
NaCl 8 0.00+0.36 19.67+ 1.47
CDDP 7 2.14+ 1.02 6.64+2.49
MCA 9 0.73+0.54 14.61+2.24
CDDP+MCA 9 2.09+0.85 7.94+ 1.50
ANOVA P=0.115 P=0.030
Table II Specific growth delay (SGD) and area under the growth
curve (AUC) for tumours of tumour line AB treated according to
schedule (b)
Treatment Mean SGD Mean AUC
group n +s.e.m. +s.e.m.
NaCl 8 0.00+0.21 16.2+1.15
CDDP 6 0.68+0.40 12.1+2.14
MCA 5 -0.05+0.26 16.2+1.61
CDDP+MCA 7 1.31+0.33 5.5+0.44
ANOVA P=0.012 P=0.0001
Table III Specific growth delay (SGD) and area under the growth
curve (AUC) for tumours of tumour line EH treated according to
schedule (b)
Treatment Mean SGD Mean AUC
group n +s.e.m. +s.e.m.
NaCl 9 0.00+0.18 10.90+1.14
CDDP 10 0.54+0.18 8.58+1.00
MCA 8 0.11+0.24 9.71+0.95
CDDP+MCA 10 1.40+0.33 4.76+1.00
ANOVA P=0.001 P=0.001
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came from populations with equal means could be rejected
only on the basis of AUC-values as the endpoint. The
distribution of AUC-values was normal for all groups, while
the distribution of SGD-values in some cases was not
normal and non-parametric tests had to be applied.
CDDP alone induced a significant inhibition of tumour
growth in tumour line AB in the first experiment with
schedule (a) (Table I) (SGD: P<0.05; AUC: P=0.001) and a
close to significant (SGD: 0.13; AUC: P=0.08) inhibition in
the second experiment with schedule (b) (Table II, Figure 2).
In tumour line EH CDDP did not induce any growth
retardation of significance (Table III, Figures 3 and 4).
MCA alone did not induce any significant reduction in
AUC regardless of treatment, schedule or tumour line used.
The addition of MCA to the CDDP treatment did not give
any significant additive effect with schedule (a). However,
using schedule (b) MCA potentiated the effect of CDDP for
both tumour line AB (SGD: P=0.245; AUC: P=0.029) and
EH (SGD: P=0.047; AUC: P=0.015). In tumour line AB
CDDP alone reduced AUC to 75% of control tumours
whereas CDDP+MCA reduced AUC to 34% of control
tumours (Figure 2). The corresponding values for tumour
line EH were 79 and 44%, respectively (Figure 4).
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Figure 2 Area under the growth curve values for control and
treated tumours of tumour line AB in schedule (b) as percentage
of NaCl-treated controls. CDDP: cisplatin, MCA: meto-
clopramide, C+M: CDDP+MCA. (Bars are mean of 5-8
tumours +s.e.m.)
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Figure 3 Growth curves of log RTS (relative tumour size) for
tumour line EH in schedule (b). CDDP: cisplatin, MCA: meto-
clopramide, C+M: CDDP +MCA. (Points are mean of 8-10
tumours +s.e.m.)
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Figure 4 Area under the growth curve values, tumour weight
day 21 and calculated volume day 21 for control and treated
tumours of tumour line EH in schedule (b) as percentage of
NaCl-treated controls. CDDP: cisplatin, MCA: metoclopramide,
C+M: CDDP+MCA. (Bars are mean of 8-10 tumours +s.e.m.)
The tumours of tumour line EH were excised and weighed
after the last measurement on day 21. The correlation
coefficient between calculated tumour volume and measured
weight was 0.939 (n = 37) and there was a strong correlation
between calculated volume and actual tumour weight, down
to at least a volume of 145mm3 (diameter 6.5mm). Neither
weight nor calculated tumour volumes at day 21 of the four
treatment groups was as sensitive as SGD and AUC to
detect induced growth inhibition (Figure 4).
Discussion
The present investigation demonstrates that MCA, a non-
cytotoxic anti-emetic drug, at the doses used in the present
study enhances the effect of CDDP without any increase in
mortality or weight loss in the xenograft tumour model
system. These effects were observed at a MCA dose com-
parable to the dose currently being administered to humans
(Gralla et al., 1981; Trope et al., 1985). This interaction has
to our knowledge not been described previously.
The rationale for using xenografted human tumours is
that they retain their sensitivity to chemotherapeutic drugs.
The relevance of this is reflected in findings that the
sensitivity of xenografted tumours to commonly used drugs
correlates to clinical experience of tumours of the same
histological type (Giovanella et al., 1978, 1983). There is also
accumulating evidence of a similar response in direct patient/
tumour comparisons (Fodstad et al., 1980; Fuji.ta et al.,
1980; Shorthouse et al., 1980; Trope & Wennerberg, 1985).
We have used perpendicular diameters to calculate tumour
volume in the evaluation of the MCA-enhancing antitumour
properties of CDDP. The accuracy of this method is sup-
ported by the present findings, where r =0.939 between
tumour volume and tumour weight was calculated. The area
under the curve (AUC), one of two endpoints used in the
present study, is superior to, for example, treatment/control
(T/G) ratio in measuring growth inhibition, since AUC
accounts for both degree and duration of growth-inhibition.
This was demonstrated in the present study when AUC
estimations, but not tumour weight or volume at day 21,
detected the initial, transient retardation of growth induced
by CDDP (Figures 3 and 4). In the xenograft model AUC
also seemed to be more sensitive than SGD (Tables I to III).
Benzamide and its analogue are known to be effective
sensitisers of ionising radiation and chemotherapeutic drugs,
which is presumably modulated via their inhibitory prop-250 E. KJELLtN et al.
erties of ADPRT (see Introduction for review). A crucial
structural feature for effective ADPRT inhibition was the
presence of a ring-carboxamide group (Sims et al., 1982), but
even when the carboxamide group is polysubstituted with
different functional groups, the properties of sensitisation of
benzamide analogues were not lost. Whether the sensitising
properties of metoclopramide can be related directly to
ADPRT modulation, as has been the case with other
benzamide analogues, is not known, but it is currently under
investigation in our laboratory.
Clinical trials are now in progress to assess the effect of
CDDP in patients with squamous cell carcinoma of the head
and neck (Morton et al., 1985; Jacobs et al., 1986). The
present finding that MCA can enhance the effect of CDDP
without any increase in toxicity, at least in an animal model,
and the fact that MCA is one of several alternate drugs that
can be chosen to control CDDP-induced nausea, suggest
important therapeutic possibilities and clearly indicate the
relevant aspects of the present study for evaluation in
humans.
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